Margaret M. Redfield

TL;DR: Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status.

TL;DR: HFpEF patients with diabetes are at increased risk of hospitalization and have reduced exercise capacity, andMultimorbidity, impaired chronotropic reserve, left ventricular hypertrophy, and activation of inflammatory, pro-oxidative, vasoconstrictor, and profibrotic pathways may contribute to adverse outcomes in HFpEF Patients with diabetes.

TL;DR: The RELAX (Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in atrial fibrillation) trial as mentioned in this paper was a multicenter randomized trial testing the impact of sildenafil on peak VO2 in stable outpatients with chronic HFpEF.

TL;DR: Although inadequate power or crossover may have contributed to negative findings in these trials, unique pathophysiology in HFpEF may mediate the differential response to neurohumoral …

TL;DR: In HFpEF, sST2 levels were associated with proinflammatory comorbidities, right ventricular pressure overload and dysfunction, and systemic congestion but not with left ventricular geometry or function, suggesting that ST2 may be a marker of systemic inflammation inHFpEF and potentially of extracardiac origin.